目的观察厄贝沙坦联合黄葵胶囊治疗慢性肾小球肾炎的效果。方法将慢性肾小球肾炎患者54例随机分为观察组和对照组各27例。观察组给予厄贝沙坦联合黄葵胶囊治疗,对照组给予厄贝沙坦治疗,比较2组临床疗效及治疗前后生化指标、血压水平。结果观察组总有效率为88.89%高于对照组的59.26%(P<0.05)。治疗前2组24h尿蛋白、血肌酐和血浆白蛋白水平比较无显著差异(P>0.05)。治疗后2组24h尿蛋白水平低于治疗前,血浆白蛋白水平高于治疗前,且观察组变化幅度大于对照组,差异均有统计学意义(P<0.05)。治疗前2组DBP、SBP水平差异无统计学意义(P>0.05)。2组治疗后血压均显著降低(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论厄贝沙坦联合黄葵胶囊治疗慢性肾炎疗效显著,可明显控制蛋白和血压水平,值得临床推广应用。 Objective To observe the effect of irbesartan combined with Huang Kui capsule in the treatment of chronic glomerulonephritis. Methods Chronic glomerulonephritis patients 54 cases were randomly divided into observation group and control group of 27 cases. The observation group was treated with irbesartan combined with Huang Kui capsule. The control group was given irbesartan treatment. The clinical efficacy, biochemical indexes and blood pressure before and after treatment were compared between the two groups. Results The total effective rate in the observation group was 88.89% higher than that in the control group (59.26%, P <0.05). There was no significant difference in 24h urine protein, serum creatinine and plasma albumin levels between the two groups before treatment (P> 0.05). The levels of 24-hour urine protein in two groups after treatment were lower than before treatment, and the levels of plasma albumin were higher than those before treatment, and the changes in observation group were greater than those in control group (P <0.05). There was no significant difference in DBP and SBP levels between the two groups before treatment (P> 0.05). The blood pressure of the two groups were significantly decreased (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion Irbesartan combined with Huang Kui capsule treatment of chronic nephritis significant effect, can significantly control the protein and blood pressure levels, worthy of clinical application.